In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Phibro Animal Health trades 18.3% above its $32.52 fair value, with valuation methods showing wide divergence—from deeply negative DCF to robust P/E and EV/EBITDA multiples. Strong liquidity and profitability contrast with low growth and leverage scores, indicating stability but limited expansion. Monte Carlo analysis reveals negligible downside risk below current price, suggesting price resilience despite mixed fundamental signals.